150 related articles for article (PubMed ID: 25201939)
1. Primary care physicians' use of FDA-approved prescription drug labels.
Sullivan HW; O'Donoghue AC; Aikin KJ
J Am Board Fam Med; 2014; 27(5):694-8. PubMed ID: 25201939
[TBL] [Abstract][Full Text] [Related]
2. Appropriate medication prescribing in elderly patients: how knowledgeable are primary care physicians? A survey study in Parma, Italy.
Maio V; Jutkowitz E; Herrera K; Abouzaid S; Negri G; Del Canale S
J Clin Pharm Ther; 2011 Aug; 36(4):468-80. PubMed ID: 21729112
[TBL] [Abstract][Full Text] [Related]
3. U.S. physician knowledge of the FDA-approved indications and evidence base for commonly prescribed drugs: results of a national survey.
Chen DT; Wynia MK; Moloney RM; Alexander GC
Pharmacoepidemiol Drug Saf; 2009 Nov; 18(11):1094-100. PubMed ID: 19697444
[TBL] [Abstract][Full Text] [Related]
4. Prescription of tamoxifen for breast cancer prevention by primary care physicians.
Armstrong K; Quistberg DA; Micco E; Domchek S; Guerra C
Arch Intern Med; 2006 Nov; 166(20):2260-5. PubMed ID: 17101945
[TBL] [Abstract][Full Text] [Related]
5. FDA drug prescribing warnings: is the black box half empty or half full?
Wagner AK; Chan KA; Dashevsky I; Raebel MA; Andrade SE; Lafata JE; Davis RL; Gurwitz JH; Soumerai SB; Platt R
Pharmacoepidemiol Drug Saf; 2006 Jun; 15(6):369-86. PubMed ID: 16294363
[TBL] [Abstract][Full Text] [Related]
6. Unapproved uses of approved drugs: the physician, the package insert, and the Food and Drug Administration: subject review. American Academy of Pediatrics Committee on Drugs.
Pediatrics; 1996 Jul; 98(1):143-5. PubMed ID: 8668390
[TBL] [Abstract][Full Text] [Related]
7. Clinical decision-making: physicians' preferences and experiences.
Murray E; Pollack L; White M; Lo B
BMC Fam Pract; 2007 Mar; 8():10. PubMed ID: 17362517
[TBL] [Abstract][Full Text] [Related]
8. Adoption of and experience with e-prescribing by primary care physicians.
Jariwala KS; Holmes ER; Banahan BF; McCaffrey DJ
Res Social Adm Pharm; 2013; 9(1):120-8. PubMed ID: 22695213
[TBL] [Abstract][Full Text] [Related]
9. Communicating quantitative risks and benefits in promotional prescription drug labeling or print advertising.
West SL; Squiers LB; McCormack L; Southwell BG; Brouwer ES; Ashok M; Lux L; Boudewyns V; O'Donoghue A; Sullivan HW
Pharmacoepidemiol Drug Saf; 2013 May; 22(5):447-58. PubMed ID: 23440924
[TBL] [Abstract][Full Text] [Related]
10. Policy versus practice: comparison of prescribing therapy and durable medical equipment in medical and educational settings.
Sneed RC; May WL; Stencel C
Pediatrics; 2004 Nov; 114(5):e612-25. PubMed ID: 15520092
[TBL] [Abstract][Full Text] [Related]
11. Off-label prescribing explained. Why your doctor may recommend meds that aren't FDA-approved for your condition.
Johns Hopkins Med Lett Health After 50; 2011 Jun; 23(4):7. PubMed ID: 21702115
[No Abstract] [Full Text] [Related]
12. Opioids for chronic nonmalignant pain. Attitudes and practices of primary care physicians in the UCSF/Stanford Collaborative Research Network. University of California, San Francisco.
Potter M; Schafer S; Gonzalez-Mendez E; Gjeltema K; Lopez A; Wu J; Pedrin R; Cozen M; Wilson R; Thom D; Croughan-Minihane M
J Fam Pract; 2001 Feb; 50(2):145-51. PubMed ID: 11219563
[TBL] [Abstract][Full Text] [Related]
13. Off-label prescribing among office-based physicians.
Radley DC; Finkelstein SN; Stafford RS
Arch Intern Med; 2006 May; 166(9):1021-6. PubMed ID: 16682577
[TBL] [Abstract][Full Text] [Related]
14. What is prescription labeling communicating to doctors about hepatotoxic drugs? A study of FDA approved product labeling.
Willy ME; Li Z
Pharmacoepidemiol Drug Saf; 2004 Apr; 13(4):201-6. PubMed ID: 15255086
[TBL] [Abstract][Full Text] [Related]
15. Understanding primary care physicians' treatment of chronic low back pain: the role of physician and practice factors.
Phelan SM; van Ryn M; Wall M; Burgess D
Pain Med; 2009 Oct; 10(7):1270-9. PubMed ID: 19818037
[TBL] [Abstract][Full Text] [Related]
16. Physicians' use of and preferences for FDA-approved prescribing information.
Sullivan HW; Squire C; Aikin KJ; Tzeng J; Ferriola-Bruckenstein K; Brodsky E; Trentacosti AM; Johnson M
Res Social Adm Pharm; 2022 Jun; 18(6):3027-3037. PubMed ID: 34364803
[TBL] [Abstract][Full Text] [Related]
17. Physician characteristics and prescription drug use during pregnancy: a population-based study.
Weng SS; Chen YH; Lin CC; Keller JJ; Wang IT; Lin HC
Ann Epidemiol; 2013 Feb; 23(2):54-9. PubMed ID: 23218810
[TBL] [Abstract][Full Text] [Related]
18. Prescription drug use in pregnancy: a retrospective, population-based study in British Columbia, Canada (2001-2006).
Daw JR; Mintzes B; Law MR; Hanley GE; Morgan SG
Clin Ther; 2012 Jan; 34(1):239-249.e2. PubMed ID: 22169049
[TBL] [Abstract][Full Text] [Related]
19. How physician obesity specialists use drugs to treat obesity.
Hendricks EJ; Rothman RB; Greenway FL
Obesity (Silver Spring); 2009 Sep; 17(9):1730-5. PubMed ID: 19300434
[TBL] [Abstract][Full Text] [Related]
20. Physicians' perceived knowledge of and responsibility for managing patients' out-of-pocket costs for prescription drugs.
Shrank WH; Asch SM; Joseph GJ; Young HN; Ettner SL; Kholodenko Y; Glassman P; Kravitz RL
Ann Pharmacother; 2006 Sep; 40(9):1534-40. PubMed ID: 16912246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
